$ELTX: One of our #ESMO2026 watchlist catalysts just reported.
Phase 2 ELI-002 7P pancreatic cancer update:
• Primary DFS endpoint misse already disclosed in June.
• New subgroup data: DFS HR 0.51 in ctDNA-negative patients; 0.57 in ctDNA-positive patients.
📊Shares pared earlier losses to −1.5%
Our pre-ESMO Prob/Mag scenarios below 👇
Next watch: Phase 3 development plans.
2604 浏览 · 4 赞 · 2 转发 · 2 回复
Proffered paper 1: Gastrointestinal tumour, upper digestive
https://esmocongress.esmo.org- BiopharmIQ by Amp@BiopharmIQ
What could the next readout mean for your ticker? Explore positive, mixed & negative scenarios with BPIQ’s Phase 2/3 Probability & Move Analysis. https://www.offers.bpiq.com/probability-move-analysis?mo=oct6
- BiopharmIQ by Amp@BiopharmIQ
Next on radar for $ELTX: Phase 1 initiation in Q4 2026 for ELI-002 7P + a RAS inhibitor ± anti-PD-1 in metastatic pancreatic cancer. Track upcoming milestones: https://app.bpiq.com/catalyst-calendar
来源：BiopharmIQ by Amp · x.com